Maximising returns: combining newborn screening with gene therapy for spinal muscular atrophy
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors The author solely contributed to this article.
Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests The author has served on spinal muscular atrophy advisory boards for Roche.
Provenance and peer review Commissioned; internally peer reviewed.